Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Rafael Fonseca MD
Rafael Fonseca MD Editor-in-Chief
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
David Henry MD
David Henry MD Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · September 28, 2024

Predictive Capability of HER2DX Genomic Assay in HER2+ Early Breast Cancer Treated With Trastuzumab and Pertuzumab

Clinical Cancer Research

 

 Save  Recommend
 Share

Additional Info

Clinical Cancer Research
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial
Clin. Cancer Res 2024 Sep 13;30(18)4123-4130, A Llombart-Cussac, J Pérez-García, F Brasó-Maristany, L Paré, G Villacampa, M Gion, P Schmid, M Colleoni, MR Borrego, P Galván, JS Parker, W Buckingham, CM Perou, P Villagrasa, JA Guerrero, M Sampayo-Cordero, M Mancino, A Prat, J Cortés

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated